Alexza Finds New U.S. Marketing Partner For Adasuve In Teva
This article was originally published in The Pink Sheet Daily
Executive Summary
A quick-acting, inhaled antipsychotic, Adasuve has been approved in the U.S. and EU, where it will be commercialized by Spain’s Grupo Ferrer. Teva takes over after previous U.S. partner Biovail stepped away upon being bought out by Valeant.